Sand Hill Global Advisors LLC cut its holdings in shares of Allergan (NYSE:AGN) by 89.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,379 shares of the company’s stock after selling 12,134 shares during the quarter. Sand Hill Global Advisors LLC’s holdings in Allergan were worth $232,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of AGN. Schwab Charles Investment Management Inc. increased its holdings in Allergan by 4.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 1,188,662 shares of the company’s stock worth $194,442,000 after purchasing an additional 48,352 shares during the last quarter. Prospera Financial Services Inc purchased a new stake in Allergan during the 4th quarter worth approximately $326,000. APG Asset Management N.V. increased its holdings in Allergan by 2.7% during the 4th quarter. APG Asset Management N.V. now owns 139,347 shares of the company’s stock worth $18,983,000 after purchasing an additional 3,638 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in Allergan by 642.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 124,231 shares of the company’s stock worth $20,322,000 after purchasing an additional 107,500 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its holdings in Allergan by 14.3% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 389,771 shares of the company’s stock worth $63,758,000 after purchasing an additional 48,765 shares during the last quarter. Institutional investors own 79.57% of the company’s stock.
In related news, EVP William Meury sold 24,425 shares of the business’s stock in a transaction that occurred on Thursday, May 17th. The stock was sold at an average price of $154.59, for a total transaction of $3,775,860.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Maria Teresa Hilado acquired 895 shares of Allergan stock in a transaction that occurred on Thursday, March 15th. The shares were bought at an average price of $167.39 per share, with a total value of $149,814.05. The disclosure for this purchase can be found here. Insiders have purchased a total of 6,095 shares of company stock valued at $936,201 in the last 90 days. Insiders own 0.36% of the company’s stock.
AGN has been the topic of several analyst reports. Credit Suisse Group set a $215.00 price objective on Allergan and gave the stock a “buy” rating in a report on Thursday, March 1st. SunTrust Banks initiated coverage on Allergan in a report on Friday, February 23rd. They set a “buy” rating and a $200.00 price objective on the stock. They noted that the move was a valuation call. Vetr upgraded Allergan from a “hold” rating to a “buy” rating and set a $189.60 price objective on the stock in a report on Thursday, February 1st. Bank of America lifted their price objective on Allergan from $208.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada restated a “buy” rating and set a $213.00 price objective on shares of Allergan in a report on Wednesday, March 14th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $214.81.
Allergan opened at $154.00 on Friday, Marketbeat Ratings reports. Allergan has a 12-month low of $142.81 and a 12-month high of $256.80. The company has a market cap of $52.10 billion, a P/E ratio of 9.42, a P/E/G ratio of 1.10 and a beta of 1.17. The company has a quick ratio of 0.94, a current ratio of 1.10 and a debt-to-equity ratio of 0.36.
Allergan (NYSE:AGN) last released its quarterly earnings data on Monday, April 30th. The company reported $3.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.36 by $0.38. Allergan had a positive return on equity of 8.53% and a negative net margin of 11.94%. The business had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same quarter in the previous year, the firm posted $3.35 EPS. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. equities analysts expect that Allergan will post 16.03 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 15th. Investors of record on Friday, May 18th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Thursday, May 17th. This represents a $2.88 dividend on an annualized basis and a yield of 1.87%. Allergan’s dividend payout ratio is currently 17.61%.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.